The WHO’s revised classification system for CNS tumours now incorporates genetic features, including the mutation status of isocitrate dehydrogenase (IDH) genes. A new article proposes that mutational status of CDKN2A and CDKN2B should also be included to facilitate grading of IDH-mutated gliomas with both prognostic and clinical relevance.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803–820 (2016).
Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).
Shirahata, M. et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. https://doi.org/10.1007/s00401-018-1849-4 (2018).
Laenkholm, A. V. et al. An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG). Acta Oncol. 57, 83–89 (2018).
Hamilton, E. & Infante, J. R. Targeting CDK4/6 in patients with cancer. Cancer Treat. Rev. 45, 129–138 (2016).
Cen, L. et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro. Oncol. 14, 870–881 (2012).
Wiedemeyer, W. R. et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc. Natl Acad. Sci. USA 107, 11501–11506 (2010).
Reis, G. F. et al. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. J. Neuropathol. Exp. Neurol. 74, 442–452 (2015).
von Deimling, A., Ono, T., Shirahata, M. & Louis, D. N. Grading of diffuse astrocytic gliomas: a review of studies before and after the advent of IDH testing. Semin. Neurol. 38, 19–23 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.Y. has ownership interest (including patents) in Agios Pharmaceuticals, PGDX and Genetron Health, and he is a board member for Genetron Health. C.J.P. declares no competing interests.
Rights and permissions
About this article
Cite this article
Pirozzi, C.J., Yan, H. Improved grading of IDH-mutated astrocytic gliomas. Nat Rev Neurol 14, 383–384 (2018). https://doi.org/10.1038/s41582-018-0019-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-018-0019-6
